December 11, 2009 - Technologie Biolactis Inc. announces the filing of a new patent protecting a major discovery with respect to the modulation of the obesity related metabolic pathway: Method of regulating PPAR, obesity related pathway and their associated metabolic impact - Technologie Biolactis Inc., a Canadian biotechnology company specializing in the development of lactoceuticals focused on cardiovascular, metabolic and obesity-associated disorders, is pleased to announce the filing of a new patent application protecting the recent discovery of an obesity related metabolic pathway modulation.Obesity is a chronic disorder of energy imbalance characterized by an excess of energy intake in the long term compared with limited energy expenditure, leading to storage of the excess energy in the form of adipose tissue. Obesity contributes directly to numerous dangerous co-morbidities, including type 2 diabetes, cardio-metabolic diseases, hepatic disorders, cardiovascular disease, inflammatory diseases, premature aging, and some forms of cancer. Obesity has reached epidemic proportions globally with more than 1 billion adults overweight, at least 300 million of them clinical obese.
Following the genomic analysis of the mechanism of action, the bioactive ingredients of BiolActis, called MPM (Malleable Protein Matrix), demonstrated the capacity to modulate specific nuclear receptor, the peroxisome proliferator activated receptors (PPARs), and some biological pathway associated to obesity.
It has been well established that PPARs agonists are key players in establishing strategy to fight obesity. The PPARs are important regulators of carbohydrate and lipid metabolism, cell growth and differentiation, immune-regulation and the inflammatory response. Biological processes modulated by PPARs include, for example, plasma lipid transport and fatty acid catabolism, regulation of insulin sensitivity and blood glucose levels, inflammatory response, weight control and body composition... Technologie BiolActis' Press Release -
